[Muscle relaxants in the ICU]

Area of Science:

• Critical Care Medicine
• Pharmacology
• Neurology

Background:

• Neuromuscular blockade use in intensive care units (ICUs) has declined with advancements in non-invasive ventilation.
• Traditional agents like succinylcholine present significant side effect profiles.
• The need for effective and safer neuromuscular blocking agents in critical care persists.

Purpose of the Study:

• To review current trends and alternatives in neuromuscular blockade for ICU patients.
• To evaluate the properties and benefits of rocuronium, atracurium, and cis-atracurium.
• To emphasize the importance of neuromuscular monitoring in the ICU setting.

Main Methods:

• Literature review of neuromuscular blocking agents used in critical care.
• Analysis of pharmacokinetic and pharmacodynamic profiles of selected agents.
• Discussion of clinical implications and monitoring strategies.

Main Results:

• Rocuronium offers rapid onset as a potential succinylcholine alternative.
• Atracurium and cis-atracurium exhibit organ-independent metabolism, simplifying use in critically ill patients.
• Neuromuscular monitoring is essential to mitigate risks such as prolonged blockade and critical illness neuropathy.

Conclusions:

• Modern neuromuscular blocking agents provide viable alternatives with improved safety profiles.
• Careful patient selection and vigilant neuromuscular monitoring are paramount in ICU settings.
• Understanding agent-specific properties is key to optimizing neuromuscular blockade therapy and preventing adverse events.